Video: Knowing when, to switch an MS Medication
Click the above to listen and learn on the topic: Knowing When, to Switch a Multiple Sclerosis (MS) Medication ~~~~~~~~~~~~~~~~~~~~…
PLEGRIDY Three-Year Data Support Long-Term Safety and Efficacy in MS Patients
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients Interim…
Stuart Schlossman
Mid-Michigan resident tests out new MS treatment
OWOSSO, MI (WNEM) – A new groundbreaking treatment for multiple sclerosis is helping slow down the disease. A patient in Owosso was the…
Stuart Schlossman
Opexa Developing Tcelna as a True Personalized MS Therapy For SPMS, RRMS
Multiple Sclerosis News Today Opexa Developing Tcelna as a True Personalized MS Therapy For SPMS, RRMS Maureen Newman After the…
Stuart Schlossman
Oral Drugs May Reduce Preference for Injectable Drugs in Multiple Sclerosis Treatment
Frost & Sullivan recently published a report entitled “A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market” providing insight into…
Stuart Schlossman
Biogen recently announced that its next-generation multiple sclerosis drug Zinbryta has been submitted for FDA approval
ABSTRACT The submission clears the way for an FDA decision early next year, and potentially sets the stage for Biogen…
Stuart Schlossman
Changing the Course of Your MS: The Disease-Modifying Drugs
If you have active relapsing-remitting MS, your doctor will first treat you with one of the disease-modifying drugs. They’re called…
Stuart Schlossman
The Monoclonal Antibody Anti-LINGO-1 Is Shown to Repair Damaged Myelin in Acute Optic Neuritis
Published in Neurology News · April 15, 2015 April 14, 2015—Washington, DC— An experimental monoclonal antibody has been shown to remyelinate in a…
Stuart Schlossman
Allegheny, PA. General Hospital Introduces New Treatment (Lemtrada) for Relapsing Multiple Sclerosis
Allegheny General Hospital, part of Allegheny Health Network, is the first hospital in the western Pennsylvania region to offer Lemtrada,…
Stuart Schlossman
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)– Today Biogen (BIIB) and AbbVie (ABBV) announced that the U.S. Food and Drug Administration (FDA) has accepted for…
Stuart Schlossman
